Wrinkles

... Federal Trade Commission Votes Unanimously to Clear Allergan's $3.2 Billion Takeover of Inamed Canadian Business Online My CB e-Newsletters My Portfolio RSS Advisory Panel Stocks Bonds Commodities Headline News Market News Earnings News M&As & IPOs Career Employees Strategy B School Live and Learn My Tech Companies Trends Lists My Watchlist My Portfolio Gotta have it Gotta do it Think About This AB BC MB NB AB NL NS NT NU ON PE QC SK YT AB BC MB NB AB NL NS NT NU ON PE QC SK YT #breadcrumbs, #breadcrumbs a {text-transform:uppercase !

important;} Markets Home Stocks Bonds/Fixed Income Commodities Income Trusts Headline News Market News Earnings News M&As and IPOs Ga...

... PharmaLive: Preserving Competition, FTC Requires Divestiture Before Allowing Allergan’s Acquisition of Inamed BUSINESS STRATEGY Preserving Competition, FTC Requires Divestiture Before Allowing Allergan’s Acquisition of Inamed Consent Order Requires Allergan to Divest Future Botox Rival Reloxin in $3.2 Billion Deal WASHINGTON, March 8, 2006-Botox marketer Allergan, Inc., and the Inamed Corporation will divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle Federal Trade Commission charges that Allergan’s $3.2 billion purchase of Inamed would violate federal antitrust laws.

The FTC alleges that Allergan’s purchase of the expected first serious competitor to Botox likely would reduce competition and force consumers to pay higher prices for the botulinum toxin type A products used by millions of Americans to temporarily erase frown lines and wrinkles.

Under the terms of the FTC settlement, the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.-based manufacturer.

On December 20, 2005, Allergan reached an agreement to acquire Inamed for approximately $3.2 billion.

Allergan’s Botox is the best-selling botulinum toxin in the United States and the only such product approved by the U.S.

Food and Drug Administration for the treatment of facial wrinkles.

In 2002, Inamed acquired the U.S.

rights to a rival botulinum toxin type A, Reloxin, from Ipsen.

Reloxin currently is in Phase III ...

... Update 1: FTC Approves Allergan Takeover of Inamed - Forbes.com '); } if (document.cookie.indexOf('partner_session=msnbc') !

= -1) { var _rsCI='us-forbes'; var _rsCG='msnbc_hat_test'; var _rsDT=1; var _rsSI=escape(window.location); var _rsLP=location.protocol.indexOf('https')=4) { var _rsRD=(new Date()).getTime(); var _rsSE=1; var _rsSV=''; var _rsSM=1.0; _rsCL=''; } else { _rsCL=''; } //document.write(_rsCL); document.write(''); } // -> Jump | Free Trial Issue Search Quote Select Section Home Investment Newsletters Polls & Discussions Premium Tools Special Reports Video & Audio IT Research Library IT Product & Service Search Forbes Digital Tool Business -Manufacturing -Technology -Commerce -Services -Energy -Healthcare -Logistics Technology -E-Business -Enterprise Tech -Infoimaging -Intelligent Infrastructure -Personal Tech -Sciences & Medicine -Wireless -CIO Network -Digital Entertainment Markets -Equities -Economy -Commodities -Bonds -Emerging Markets -Currencies Entrepreneurs -Finance -Human Resources -Law & Taxation -Sales & Marketing -Management -Technology Work -Careers -Compensation -Management Lists -Companies -Forbes Global 2000 -200 Best Small Cos.

-400 Best Big Cos.

-Largest Private Cos.

-People -World's Richest People -100 Top Celebrities -400 Richest Americans -Best Paid CEOs -Places -Best Places Pers...